Yi-You Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yi-You Huang has a total of 162 co-authors. Here are the top co-authors by number of shared publications:
- Hai-Bin Luo
Key Laboratory of Tropical Biological Resources of Ministry of Education and Hainan Engineering Research Center for Drug Screening and Evaluation, School of Pharmaceutical Sciences, Hainan University, Haikou, China
13 shared publications Xue Wang
Key Laboratory of Tropical Biological Resources of Ministry of Education and Hainan Engineering Research Center for Drug Screening and Evaluation, School of Pharmaceutical Sciences
6 shared publicationsXingfu Liu
Key Laboratory of Tropical Biological Resources of Ministry of Education and and Hainan Engineering Research Center for Drug Screening and Evaluation, School of Pharmaceutical Sciences, Hainan University, Haikou 570228, China
5 shared publicationsFurong Zhang
4 shared publicationsHai-Bin Luo
Key Laboratory of Tropical Biological Resources of Ministry of Education and and Hainan Engineering Research Center for Drug Screening and Evaluation, School of Pharmaceutical Sciences, Hainan University, Haikou 570228, China; Song Li's Academician Workstation of Hainan University (School of Pharmaceutical Sciences), Yazhou Bay, Sanya 572000, China
4 shared publications- Qian Zhou
Key Laboratory of Tropical Biological Resources of Ministry of Education and Hainan Engineering Research Center for Drug Screening and Evaluation, School of Pharmaceutical Sciences, Hainan University, Haikou, China
4 shared publications
Latest Publications
- Open Access
- 23 April 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18  (5) , 516
Design, Synthesis, and Evaluation of Braylin Derivatives as Novel PDE4 Inhibitors with Anti-Inflammatory Effects
Background/Objectives: PDE4 is a key regulator of cAMP signaling and a clinically validated anti-inflammatory target; however, the use of PDE4 inhibitors is often limited by adverse effects such as nausea, vomiting, and diarrhea. The natural compound braylin was previously identified as a novel PDE4 inhibitor scaffold, exhibiting an IC50 of 0.96 µM. Using the PDE4–braylin co-crystal structure, we conducted structure-based design and optimization to enhance its potency. Methods: A series of novel braylin derivatives was synthesized and characterized. Their inhibitory activities against PDE4D were evaluated via enzymatic assays, and binding thermodynamics were analyzed by isothermal titration calorimetry (ITC). Molecular modeling was used to predict binding modes, and anti-inflammatory effects were assessed in LPS-stimulated macrophages. Results: Structure-guided optimization yielded lead compound L27, which showed significantly improved PDE4D inhibition (IC50 = 67 nM) and high-affinity binding (Kd = 45 nM) as confirmed by ITC. L27 also exhibited remarkable selectivity against PDE isoforms. Molecular simulations highlighted key interactions with Gln369 and hydrophobic residues in the PDE4 active site. In cellular assays, L27 dose-dependently suppressed LPS-induced inflammation in macrophages at non-cytotoxic concentrations with efficacy comparable to roflumilast. Conclusions: We developed L27, a potent and selective PDE4 inhibitor derived from natural braylin. It demonstrated promising in vitro anti-inflammatory activity and represents a valuable lead for further therapeutic development.
- 23 April 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18  (5) , 516
Open AccessDesign, Synthesis, and Evaluation of Braylin Derivatives as Novel PDE4 Inhibitors with Anti-Inflammatory Effects
Background/Objectives: PDE4 is a key regulator of cAMP signaling and a clinically validated anti-inflammatory target; however, the use of PDE4 inhibitors is often limited by adverse effects such as nausea, vomiting, and diarrhea. The natural compound braylin was previously identified as a novel PDE4 inhibitor scaffold, exhibiting an IC50 of 0.96 µM. Using the PDE4–braylin co-crystal structure, we conducted structure-based design and optimization to enhance its potency. Methods: A series of novel braylin derivatives was synthesized and characterized. Their inhibitory activities against PDE4D were evaluated via enzymatic assays, and binding thermodynamics were analyzed by isothermal titration calorimetry (ITC). Molecular modeling was used to predict binding modes, and anti-inflammatory effects were assessed in LPS-stimulated macrophages. Results: Structure-guided optimization yielded lead compound L27, which showed significantly improved PDE4D inhibition (IC50 = 67 nM) and high-affinity binding (Kd = 45 nM) as confirmed by ITC. L27 also exhibited remarkable selectivity against PDE isoforms. Molecular simulations highlighted key interactions with Gln369 and hydrophobic residues in the PDE4 active site. In cellular assays, L27 dose-dependently suppressed LPS-induced inflammation in macrophages at non-cytotoxic concentrations with efficacy comparable to roflumilast. Conclusions: We developed L27, a potent and selective PDE4 inhibitor derived from natural braylin. It demonstrated promising in vitro anti-inflammatory activity and represents a valuable lead for further therapeutic development.
- 23 January 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69  (3) , 2400-2423
Discovery of Novel MDH2 Inhibitor 28i by Secondary Development of Glibenclamide with Potent Antiaging Activities
Aging is a major public health challenge that urgently requires effective pharmacological interventions. We previously identified mitochondrial malate dehydrogenase 2 (MDH2) as a regulator of aging and discovered that the approved drug glibenclamide (Gli) can inhibit MDH2 and delay aging, but is limited by weak potency and hypoglycemia. Herein, we employed a rational secondary development strategy to optimize Gli and discovered compound 28i, a potent MDH2 inhibitor that extended lifespan and improved healthspan in Caenorhabditis elegans. In multiple mammalian cell models, 28i significantly reduced senescence markers, and in both doxorubicin-induced and naturally aged mice, it alleviated tissue aging and suppressed SASP factors. Importantly, 28i displayed low acute toxicity (LD50 > 1000 mg/kg), minimal hERG channel inhibition (IC50 > 40 μM), and lacked hypoglycemic effect in oral glucose tolerance tests. Collectively, these findings validate 28i as a highly promising nonhypoglycemic MDH2 inhibitor for future clinical translation as a gerotherapeutic candidate.
- 23 January 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69  (3) , 2400-2423
Discovery of Novel MDH2 Inhibitor 28i by Secondary Development of Glibenclamide with Potent Antiaging Activities
Aging is a major public health challenge that urgently requires effective pharmacological interventions. We previously identified mitochondrial malate dehydrogenase 2 (MDH2) as a regulator of aging and discovered that the approved drug glibenclamide (Gli) can inhibit MDH2 and delay aging, but is limited by weak potency and hypoglycemia. Herein, we employed a rational secondary development strategy to optimize Gli and discovered compound 28i, a potent MDH2 inhibitor that extended lifespan and improved healthspan in Caenorhabditis elegans. In multiple mammalian cell models, 28i significantly reduced senescence markers, and in both doxorubicin-induced and naturally aged mice, it alleviated tissue aging and suppressed SASP factors. Importantly, 28i displayed low acute toxicity (LD50 > 1000 mg/kg), minimal hERG channel inhibition (IC50 > 40 μM), and lacked hypoglycemic effect in oral glucose tolerance tests. Collectively, these findings validate 28i as a highly promising nonhypoglycemic MDH2 inhibitor for future clinical translation as a gerotherapeutic candidate.
- 22 December 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 169, 109414
Discovery of pinoresinol dimethyl ether as a natural PDE4 inhibitor with anti-psoriatic effects
- 22 December 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 169, 109414
Discovery of pinoresinol dimethyl ether as a natural PDE4 inhibitor with anti-psoriatic effects
- 21 November 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68  (23) , 25290-25306
Structure-Based Optimization of Imidazopyridine Derivatives as Selective and Orally Bioavailable Phosphodiesterase 10A Inhibitors with Reduced Blood–Brain Barrier Penetration for the Treatment of Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (PF) is a debilitating, progressive, and severe interstitial lung disease that lacks an effective treatment. The overexpression of phosphodiesterase 10A (PDE10A) is closely associated with the development of PF. However, few selective PDE10A inhibitors with favorable drug-like properties are orally available for the treatment of PF. Structure-based optimization of compound A30 has led to the development of compound QC-3, which exhibits an IC50 of 6.2 nM against PDE10A, excellent selectivity among PDEs, favorable drug-like properties, and reduced blood–brain barrier penetration. In a bleomycin-induced murine model of PF, oral administration of QC-3 (10 mg/kg, once daily) demonstrated superior antifibrotic efficacy compared to pirfenidone (300 mg/kg, once daily), while exhibiting minimal cerebral residue, thereby reducing its potential risk of central nervous system suppression. Moreover, QC-3 attenuates PF by blocking myofibroblast differentiation through the cAMP/PKA/CREB signaling pathway, highlighting that inhibition of PDE10A provides a novel and promising therapeutic strategy for PF.
- 21 November 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68  (23) , 25290-25306
Structure-Based Optimization of Imidazopyridine Derivatives as Selective and Orally Bioavailable Phosphodiesterase 10A Inhibitors with Reduced Blood–Brain Barrier Penetration for the Treatment of Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (PF) is a debilitating, progressive, and severe interstitial lung disease that lacks an effective treatment. The overexpression of phosphodiesterase 10A (PDE10A) is closely associated with the development of PF. However, few selective PDE10A inhibitors with favorable drug-like properties are orally available for the treatment of PF. Structure-based optimization of compound A30 has led to the development of compound QC-3, which exhibits an IC50 of 6.2 nM against PDE10A, excellent selectivity among PDEs, favorable drug-like properties, and reduced blood–brain barrier penetration. In a bleomycin-induced murine model of PF, oral administration of QC-3 (10 mg/kg, once daily) demonstrated superior antifibrotic efficacy compared to pirfenidone (300 mg/kg, once daily), while exhibiting minimal cerebral residue, thereby reducing its potential risk of central nervous system suppression. Moreover, QC-3 attenuates PF by blocking myofibroblast differentiation through the cAMP/PKA/CREB signaling pathway, highlighting that inhibition of PDE10A provides a novel and promising therapeutic strategy for PF.
- 18 November 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68  (22) , 24436-24455
Artificial Intelligence-Driven Discovery of Pyrazolo[1,5- a ]pyrimidine Derivatives as Novel Phosphodiesterase 4 Inhibitors for Treating Idiopathic Pulmonary Fibrosis
Phosphodiesterase 4 (PDE4) has been validated as a promising therapeutic target for idiopathic pulmonary fibrosis (IPF), a devastating interstitial lung disease lacking really effective therapeutic drugs, particularly exacerbated in the post-COVID-19 era. Herein, we reported the discovery of 13c, a novel pyrazolo[1,5-a]pyrimidine-based PDE4 inhibitor, via an innovative artificial intelligence (AI)-driven virtual screening approach integrated with structure-based design. The cocrystal analysis of PDE4-13c elucidated the structural basis of its high affinity, revealing that the unique "halogen-binding and metal-coordination" synergistic network significantly influenced PDE4 inhibitory activity, which resulted in a 268-fold potency enhancement (IC50 = 2.7 nM) over hit T3700 (IC50 = 725 nM). Notably, 13c exhibited remarkable hepatic microsomal stability (RLM1/2 = 141.4 min). Furthermore, 13c exhibited remarkable antifibrotic activity in vitro and significantly attenuated bleomycin-induced pulmonary fibrosis in vivo, highlighting its potential as a novel PDE4 inhibitor for IPF.
- 18 November 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68  (22) , 24436-24455
Artificial Intelligence-Driven Discovery of Pyrazolo[1,5- a ]pyrimidine Derivatives as Novel Phosphodiesterase 4 Inhibitors for Treating Idiopathic Pulmonary Fibrosis
Phosphodiesterase 4 (PDE4) has been validated as a promising therapeutic target for idiopathic pulmonary fibrosis (IPF), a devastating interstitial lung disease lacking really effective therapeutic drugs, particularly exacerbated in the post-COVID-19 era. Herein, we reported the discovery of 13c, a novel pyrazolo[1,5-a]pyrimidine-based PDE4 inhibitor, via an innovative artificial intelligence (AI)-driven virtual screening approach integrated with structure-based design. The cocrystal analysis of PDE4-13c elucidated the structural basis of its high affinity, revealing that the unique "halogen-binding and metal-coordination" synergistic network significantly influenced PDE4 inhibitory activity, which resulted in a 268-fold potency enhancement (IC50 = 2.7 nM) over hit T3700 (IC50 = 725 nM). Notably, 13c exhibited remarkable hepatic microsomal stability (RLM1/2 = 141.4 min). Furthermore, 13c exhibited remarkable antifibrotic activity in vitro and significantly attenuated bleomycin-induced pulmonary fibrosis in vivo, highlighting its potential as a novel PDE4 inhibitor for IPF.
- 24 October 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 302  (Pt 1) , 118302
Discovery of novel 2,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridine-7-one derivatives as PDE2 inhibitors with Alzheimer's disease therapeutic potential
- 24 October 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 302  (Pt 1) , 118302
Discovery of novel 2,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridine-7-one derivatives as PDE2 inhibitors with Alzheimer's disease therapeutic potential
- 22 April 2025
- Published by Elsevier in Chinese Chemical Letters
- Vol. 37  (5)
Plasma metabolites-based drug design: Discovery of novel and highly selective phosphodiesterase 5 inhibitors
- 22 April 2025
- Published by Elsevier in Chinese Chemical Letters
- Vol. 37  (5)
Plasma metabolites-based drug design: Discovery of novel and highly selective phosphodiesterase 5 inhibitors
- 24 December 2024
- Published by Elsevier in Chinese Chemical Letters
- Vol. 36  (10)
Platycladus orientalis (L.) Franco demonstrates effective anti-psoriasis effects by inhibiting PDE4 with favorable safety profiles
- 24 December 2024
- Published by Elsevier in Chinese Chemical Letters
- Vol. 36  (10)
Platycladus orientalis (L.) Franco demonstrates effective anti-psoriasis effects by inhibiting PDE4 with favorable safety profiles